Novo Nordisk Q2 FY26 adjusted operating profit rises 11% to DKK 33.39 billion; net sales increase 3% to DKK 78.49 billion - NVO News | RalliesNovo Nordisk Q2 FY26 adjusted operating profit rises 11% to DKK 33.39 billion; net sales increase 3% to DKK 78.49 billion
N
NVO• Updated 2026 outlook
- 2026 outlook raised: adjusted net sales growth seen at 0% to -6%, adjusted operating profit growth at 0% to -6%.
Q2 and first-half results
- Novo Nordisk Q2 2026 net sales rose 2% to DKK 78.49 billion; operating profit fell 19% to DKK 27.06 billion.
- Adjusted operating profit climbed 8% to DKK 33.39 billion, excluding DKK 6.3 billion in non-cash impairment charges on pipeline intangibles.
- H1 2026 net sales increased 13% to DKK 175.31 billion; operating profit rose 20% to DKK 86.68 billion.
Wegovy rollout and prescription trends
- Wegovy pill weekly prescriptions in the U.S. topped 265,000 for the week ending July 17; launches expanded to the UAE in June and the UK in July.
